TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03916016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Integrated Behavioral Health Care
Description: The intervention involved moving from HFHC's previous collaborative model, where medical and behavioral providers worked with each other episodically, to a more fully integrated collaborative care model with care coordination, shared treatment plans, shared service provision, and shared record keeping. To achieve this enhanced level of integration, HFHC changed its current primary care workflow to include a behavioral health specialist who conducted assessments, provided initial counseling (individual or group), and coordinated referrals to care management and/or community-based health services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: A collaborative model where medical and behavioral providers worked with each other episodically
Study: NCT00641342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: onlay mesh
Description: StomaMesh (Precut heavyweight polypropylene mesh) Vypro Mesh (lightweight Prolene and vicryl mesh)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: onlay mesh
Description: StomaMesh (Precut heavyweight polypropylene mesh) Vypro Mesh (lightweight Prolene and vicryl mesh)
Study: NCT02275728

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eletromyography Biofeedback
Study: NCT04035096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 1. Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~2. The final dose will be kept for 12 weeks.~3. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: 1. Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~2. Usual care
Study: NCT00784732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAV680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAV680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate
Study: NCT05805748

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: serious game rehabilitation
Description: The SG rehabilitation was proposed to be played four times per week for three weeks, for a total of 12 sessions, with 15 min per session (= 60 minutes per week). Conventional rehabilitation comprised five sessions of 45 min of neuropsychological rehabilitation using classical exploration training (= 225 minutes per week).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: serious game rehabilitation
Description: The SG rehabilitation was proposed to be played four times per week for three weeks, for a total of 12 sessions, with 15 min per session (= 60 minutes per week). Conventional rehabilitation comprised five sessions of 45 min of neuropsychological rehabilitation using classical exploration training (= 225 minutes per week).
Study: NCT04041427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole Pill
Description: Albendazole 400mg po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole Pill
Description: Albendazole 400mg po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole Pill
Description: Albendazole 400mg po

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat content diet
Description: High fat content diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate fat content die
Description: Moderate fat content die
Study: NCT01077180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the Rheos System
Description: Open label
Study: NCT02496832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluoroazomycin arabinoside
Study: NCT03402685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearSight
Description: Patients in the intervention group receive management of volume and vasopressor settings according to the non-invasive ClearSight system.
Study: NCT00417807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesilate
Study: NCT01077180

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care medical management
Description: Patients will continue with medical therapy for standard of care of their hypertension.
Study: NCT04292990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Patch releasing drug at the rate of 25 µg/hour, increasing by 25 µg/hour increments to maintain the NRS score≤3 after the frst 24 hours according to no change in pain control. The maximum dose allowed in this study is 300 µg/hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Tablets taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: starting at 30 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
Study: NCT00378898

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BRAVO capsule

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy
Description: one time xray to determine evacuation of bravo

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham BRAVO capsule placement
Study: NCT03456856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Film-coated tablets taken orally with food twice a day. Tablets supplied in strengths of 5.0 mg and 7.5 mg. 5.0 tablets were split into equal halves for dosages of 2.5 mg.
Study: NCT00476294

Intervention type: OTHER
Intervention: Telephone Questionnaire
Description: Follow-Up Telephone Calls Every 6 Months for 5 Years.

Intervention type: OTHER
Intervention: Telephone Questionnaire
Description: Follow-Up Telephone Calls Every 6 Months for 5 Years.
Study: NCT03510871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab, ipilimumab
Description: All enrolled subjects will receive nivolumab 3 mg/kg plus ipilimumab 1 mg/kg intravenously on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
Study: NCT05270226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE)
Description: The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE) is an innovative program that aim to improve occupational performance at work of adults with ADHD, by enhancing their EF abilities, self-awareness, and personal strategy use.~The Work-MATE is a short, synchronous and hybrid teleintervention program of eleven 1-hour weekly individual sessions. It offers a written standardized protocol, which include uniform structure of each intervention session and pool of therapy aids (for self-tailored matching by occupational therapists).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE)
Description: The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE) is an innovative program that aim to improve occupational performance at work of adults with ADHD, by enhancing their EF abilities, self-awareness, and personal strategy use.~The Work-MATE is a short, synchronous and hybrid teleintervention program of eleven 1-hour weekly individual sessions. It offers a written standardized protocol, which include uniform structure of each intervention session and pool of therapy aids (for self-tailored matching by occupational therapists).
Study: NCT02680210

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires and cognitive measures
Study: NCT04019860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating
Description: Restricted daily window of caloric intake to maximum 10 hours. Intervention period will be seven weeks.
Study: NCT03897218

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oatmeal flakes with prebiotic food supplements
Description: The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oatmeal flakes with prebiotic food supplements
Description: The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
Study: NCT02943876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized depression risk information
Description: The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
Study: NCT03897218

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: millet flakes
Description: The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
Study: NCT01474382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OraVerse
Description: 1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: No drug administered, simulation of injection used in same manner as drug
Study: NCT01643876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palatal brushing
Description: Participants will be instructed to brush their palate with a manual soft-bristle brush after each meal and before sleeping for a period of 3 months. They will be asked to keep to their usual oral and denture hygiene routine during the trial to allow the isolation of the effect of palatal brushing.
Study: NCT04739397

Intervention type: DEVICE
Intervention: Glare Testing
Description: Vision in Cataract patients were tested with and without the EpiGlare Tester

Intervention type: DEVICE
Intervention: Glare Testing
Description: Vision in Cataract patients were tested with and without the EpiGlare Tester
Study: NCT02525913

Intervention type: DEVICE
Group type: OTHER
Intervention: RFA Applicator
Study: NCT01995552

Intervention type: DEVICE
Group type: OTHER
Intervention: External Loop Recorder
Study: NCT01665989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Program
Study: NCT03580317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EA+ Carbamazepine
Description: Acupoints selection: Si-bai(ST2), Xia-guan(ST7), Di-cang(ST4), Quan-liao(SI18), Jia-che(ST6) and A-shi-xue of affected side. He-gu(LI4) and Wai-guan(TE5) of two sides.~Operation:The needles(0.18×25 mm) will be selected to stimulate the local points with shallow row needling according to the distribution of neuropathy branch of trigeminal neuralgia.The needles(0.25×40mm) will be selected to stimulate the distal acupoints. The Xia-guan(ST7) and Quan-liao(SL18) (or Jia-che(ST6)), He-gu(LI4) and Wai-guan(SJ5) acupoints will be received EA treatment by HuaTuo SDZ-ⅡB acupoint neural stimulator. The EA parameter is 2/100 Hz, 60 minutes and the current intensity is comfortable to subjects. Carbamazepine tablets should be took orally, 0.1g each time, thrice daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EA+Placebo
Description: In this group, the selection, positioning and manipulation of acupoints, the frequency, duration and retaining needle time of treatment are same as EA + Carbamazepine Group; placebo, that appearance and specifications are the same as carbamazepine, are cooperated taken of dose 0.1g, thrice daily.
Study: NCT01976494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The domestic PCA equipment 'Accufuser Omnibus®'
Description: * Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imported PCA equipment 'Infusor SV®, Baxter, USA'
Description: * Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab.
Study: NCT03725904

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Progesterone analysis in saliva
Description: Analysis of salava progesterone
Study: NCT03318822

Intervention type: DEVICE
Intervention: Q-Collar
Description: An externally-worn medical device that applies mild jugular compression
Study: NCT03820518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Study: NCT01896596

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate
Description: Administered with routine vaccinations at 3 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menitorix
Description: Administered with routine vaccinations at 3 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NeisVac-C
Description: Administered with routine vaccinations at 3 months
Study: NCT01909635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Feelings

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other Feelings
Study: NCT04060706

Intervention type: RADIATION
Intervention: Radical Image-Guided Radiotherapy
Description: Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy

Intervention type: RADIATION
Intervention: Radical Image-Guided Radiotherapy
Description: Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy

Intervention type: RADIATION
Intervention: Radical Image-Guided Radiotherapy
Description: Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy

Intervention type: RADIATION
Intervention: Radical Image-Guided Radiotherapy
Description: Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy
Study: NCT03316599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
Study: NCT03161015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: Oral
Study: NCT03313440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High wheat fiber
Description: Daily increased fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fiber
Description: Control low fiber intervention. Products are provided in boxes that must be consumed each day during the intervention.
Study: NCT03756805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: upper airway stimulation
Description: One group of patients with UAS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: One group of patients with CPAP
Study: NCT02940158

Intervention type: OTHER
Group type: OTHER
Intervention: 1/4 cup- Small red lentil
Study: NCT01665989

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Visits with a dietitian at nutrition services at MGH
Study: NCT01243567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution
Description: Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% ophthalmic solution
Description: Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
Study: NCT00607854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibritumomab Tiuxetan (Zevalin)
Description: Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.~Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)
Study: NCT02267954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu edited
Description: The menu is edited to change price label to 50% of actual value and calorie label to 50% of the actual value, along with other changes.
Study: NCT01152515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
Study: NCT01812369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMCITABINE CISPLATINE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
Study: NCT03926312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart device-based cardiac rehabilitation
Description: A smart device coupled with remote monitoring will be used to increase physical activity of patients after myocardial infarction with a history of low physical activity.
Study: NCT01301105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: 8 week class in stress reduction through instruction in mindfulness related techniques.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Enhancement Program (HEP)
Description: 8-week intervention designed to be structurally equivalent to MBSR but without a mindfulness component. Consists of nutrition, functional movement, physical activity, and music therapy.
Study: NCT03580824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 in Matrix- M adjuvant vaccine
Description: R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 in Matrix- M adjuvant vaccine
Description: R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 in Matrix- M adjuvant vaccine
Description: R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
Study: NCT06000306

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Droplet PCR
Description: Measurable residual disease Monitoring by Digital Droplet PCR in the Early Posttransplant Period

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Droplet PCR
Description: Measurable residual disease Monitoring by Digital Droplet PCR in the Early Posttransplant Period
Study: NCT03246490

Intervention type: OTHER
Group type: OTHER
Intervention: All Participants
Description: all participants will participate in the same protocol involving drinking alcohol to a .08 g% blood alcohol level
Study: NCT04251975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice
Study: NCT02940158

Intervention type: OTHER
Group type: OTHER
Intervention: 1/4 cup- Small green lentil
Study: NCT02126566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Administration of light therapy - measurement of results before and after therapy
Study: NCT02922166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRX246
Description: oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule